Summary
This study involves real-time molecular profiling of brain or other central nervous system (CNS) tumours by analysing tissue, cerebrospinal fluid (CSF), and blood plasma at critical points throughout cancer diagnosis, treatment, and recurrence. Molecular profiling is like taking a detailed snapshop of a tumour's genetic makeup, helping doctors identify specific changes or mutations to guide effective treatment choices.
You may be eligible for this study if you are aged 18 or older with a known or strong suspicion of primary CNS cancer, suitable for systemic treatment.
Biospecimens including tumour tissue, blood and CSF will be collected longitudinally from participants during routine care procedures and/or by accessing stored material. Clinical data will be collected throughout the study. Biospecimens collected will be molecularly profiled.
Molecular profiling analysis will include targeted panel sequencing, whole genome transcriptome sequencing and methylation array using tumour tissue samples. Results will be returned to the treating clinicians, accompanied by interpretation and recommendations from the molecular tumour board. By integrating clinical, molecular, histopathological, and radiological data, the project seeks to improve patient outcomes and establish feasability of molecular profiling in CNS tumours.
https://www.thebraincancercentre.org.au/